MX375805B - Microbiota ibs y sus usos. - Google Patents

Microbiota ibs y sus usos.

Info

Publication number
MX375805B
MX375805B MX2016014329A MX2016014329A MX375805B MX 375805 B MX375805 B MX 375805B MX 2016014329 A MX2016014329 A MX 2016014329A MX 2016014329 A MX2016014329 A MX 2016014329A MX 375805 B MX375805 B MX 375805B
Authority
MX
Mexico
Prior art keywords
microbiome
certain embodiments
bacterial
tract
ibs
Prior art date
Application number
MX2016014329A
Other languages
English (en)
Other versions
MX2016014329A (es
Inventor
Anthony Fodor
Enoch Bortey
Pam Golden
William Forbes
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Publication of MX2016014329A publication Critical patent/MX2016014329A/es
Publication of MX375805B publication Critical patent/MX375805B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
    • C07G11/00—Antibiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente solicitud proporciona métodos para diagnosticar y tratar a un individuo que tiene IBS (síndrome de intestino irritado). En ciertas modalidades, los métodos también incluyen diagnosticar a los individuos que responderán al tratamiento de IBS con rifaximina. Los métodos incluyen determinar la identidad y prevalencia de la comunidad bacteriana en el tracto gastrointestinal (GI). En ciertas modalidades, el microbioma comprende el microbioma del tracto GI. En ciertas modalidades, el microbioma comprende la población bacteriana del tracto gastrointestinal. En ciertas modalidades, el microbioma comprende bacterias de heces. Los métodos incluyen el análisis de la identidad de la comunidad bacteriana en el microbioma gastrointestinal para generar un perfil de la diversisda de las comunidades bacterianas.
MX2016014329A 2014-05-04 2015-05-04 Microbiota ibs y sus usos. MX375805B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461988293P 2014-05-04 2014-05-04
US201461988841P 2014-05-05 2014-05-05
US201462036085P 2014-08-11 2014-08-11
US201562135658P 2015-03-19 2015-03-19
PCT/US2015/029040 WO2015171493A1 (en) 2014-05-04 2015-05-04 Ibs microbiota and uses thereof

Publications (2)

Publication Number Publication Date
MX2016014329A MX2016014329A (es) 2017-02-23
MX375805B true MX375805B (es) 2025-03-07

Family

ID=54392878

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014329A MX375805B (es) 2014-05-04 2015-05-04 Microbiota ibs y sus usos.

Country Status (7)

Country Link
US (1) US10493064B2 (es)
EP (1) EP3140313B1 (es)
JP (1) JP6693946B2 (es)
CN (1) CN106795192B (es)
CA (1) CA2947962C (es)
MX (1) MX375805B (es)
WO (1) WO2015171493A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105543385B (zh) * 2016-01-29 2024-12-06 山东大学齐鲁医院 肠易激综合征微生物标志物及其应用
GB201617519D0 (en) 2016-10-14 2016-11-30 Genetic Analysis As A companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant
US20210278416A1 (en) * 2017-05-09 2021-09-09 The Broad Institute, Inc. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
SG11201913701VA (en) * 2017-07-17 2020-02-27 smartDNA Pty Ltd Method of diagnosing a dysbiosis
CA3101541A1 (en) * 2018-06-07 2019-12-12 4D Pharma Plc Method for stratifying ibs patients
JP7295547B2 (ja) * 2018-11-13 2023-06-21 株式会社サイキンソー 腸内ｄｙｓｂｉｏｓｉｓ判定システム
WO2020149719A2 (ko) * 2019-01-18 2020-07-23 주식회사 천랩 과민성대장증후군 특이적 미생물 바이오마커와 이를 이용하여 과민성대장증후군의 위험도를 예측하는 방법
KR102330639B1 (ko) * 2019-01-18 2021-11-24 주식회사 천랩 과민성대장증후군 특이적 미생물 바이오마커와 이를 이용하여 과민성대장증후군의 위험도를 예측하는 방법
CN114127317A (zh) * 2019-04-03 2022-03-01 4D制药科克有限公司 诊断疾病的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132908A (en) 1962-04-02 1964-05-12 Carrier Corp Thrust bearing construction
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
FR2867653B1 (fr) 2004-03-12 2008-08-08 Brandt Ind Module d'assemblage de bobines d'induction d'une zone de cuisson par chauffage par induction et zone de cuisson comprenant lesdits modules
US7807622B2 (en) * 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
WO2007124591A1 (en) * 2006-05-03 2007-11-08 University Of Manitoba Microbial markers of inflammatory bowel disease
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US8383151B2 (en) 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
SG10201607926VA (en) * 2008-02-25 2016-11-29 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
KR20100122937A (ko) * 2008-02-26 2010-11-23 샐릭스 파마슈티컬스 리미티드 장 질환의 치료 방법
US20120264637A1 (en) * 2009-06-26 2012-10-18 The Regents Of The University Of California Methods and systems for phylogenetic analysis
DK2446062T3 (da) * 2009-06-26 2014-10-06 Univ California Fremgangsmåder og systemer til phylogenetisk analyse
WO2011043654A1 (en) * 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
EP3650022A1 (en) * 2010-02-18 2020-05-13 Salix Pharmaceuticals, Ltd. Methods for treating rifampin resistant clostridium difficilis infections
US8513275B2 (en) 2010-06-03 2013-08-20 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EP3750526A1 (en) 2010-07-12 2020-12-16 Salix Pharmaceuticals, Inc. Formulations of rifaximin and uses thereof
GB201021397D0 (en) * 2010-12-16 2011-01-26 Genetic Analysis As Diagnosis of Crohn's disease
MX350448B (es) 2011-02-11 2017-09-07 Salix Pharmaceuticals Ltd Formas de rifaximina y usos de las mismas.
PL2773205T3 (pl) * 2011-11-02 2024-09-02 Salix Pharmaceuticals, Inc. Ryfaksymina w leczeniu ustępującej biegunki z przewagą zespołu jelita drażliwego

Also Published As

Publication number Publication date
CN106795192B (zh) 2020-06-16
EP3140313B1 (en) 2020-02-26
US20170151220A1 (en) 2017-06-01
CA2947962A1 (en) 2015-11-12
JP6693946B2 (ja) 2020-05-13
EP3140313A1 (en) 2017-03-15
CA2947962C (en) 2024-01-16
EP3140313A4 (en) 2017-12-27
WO2015171493A1 (en) 2015-11-12
JP2017514530A (ja) 2017-06-08
WO2015171493A9 (en) 2016-04-28
US10493064B2 (en) 2019-12-03
CN106795192A (zh) 2017-05-31
MX2016014329A (es) 2017-02-23

Similar Documents

Publication Publication Date Title
MX375805B (es) Microbiota ibs y sus usos.
EA201790010A1 (ru) Гамма-дельта t-клетки и их применение
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
EA201691607A1 (ru) Микроорганоиды и способы их получения и применения
MX2013001362A (es) Inmunoglubinas de dominio variable doble y usos de las mismas.
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
EA201691314A1 (ru) Терапевтические способы и композиции
BR112015028338A2 (pt) métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
WO2016085632A3 (en) Microfluidic measurements of the response of an organism to a drug
ECSP12011885A (es) Inmunoglobulinas con dominio variable dual
EA201690465A1 (ru) Способ оценки эффектов композиции, содержащей микроорганизмы, на кишечную микробиоту
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
MX2019006948A (es) Probioticos para su uso en el tratamiento de diverticulosis y enfermed diverticular.
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
WO2017040526A3 (en) Splice variants associated with neomorphic sf3b1 mutants
BR112016023752A2 (pt) utilização de lactobacillus rhamnosus para promover a recuperação da diversidade da microbiota intestinal após disbiose
GB2531213A (en) Systems and methods for high throughput analysis of conformation in biological entities
WO2016168344A8 (en) Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
WO2014042828A3 (en) Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
WO2016168359A8 (en) Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
CY1122474T1 (el) Μεθοδος διαγνωσης νευραλγιας του τριδυμου
DK3139940T3 (da) Sammensætning omfattende l. reuteri ler03 og l. salivarius ls06 til anvendelse til behandling af tumorer, aids og leukæmi
DK3232928T3 (da) Apparat og fremgangsmåde til ikke-invasiv bestemmelse af koncentrationen af en analyt

Legal Events

Date Code Title Description
FG Grant or registration